Objective To investigate the clinical efficacy and safety of early application of Dapagliflozin in patients undergoing emergency percutaneous coronary intervention（PCI）after acute myocardial infarction（AMI）. Methods AMI patients undergoing emergency PCI（n = 68）were chosen from the Tengzhou Central People′s Hospital from September 2020 to September 2021，and divided randomly into control group（n = 34）and research group（n = 34）. Both groups of patients were given aspirin，ticagrelor，etc after PCI. The control group received conventional treatments such as metoprolol perindopril ，and the research group received dapagliflozin on bases of conventional oral medicine，a course for 6 months. The level of N ⁃terminal pro ⁃B ⁃type natriuretic peptide（NT ⁃ proBNP），left ventricular ejection fraction（LVEF），left ventricular end diastolic volume（LVEDV），left ventricular end systolic volume（LVESV），ventricular remodeling rate，the incidence of heart failure，the readmission rate， and incidence of adverse reactions were compared between the two groups. Results After 1 month and 6 months of treatment，the levels of NT⁃proBNP in the two groups were significantly lower than before treatment（P < 0.05）， and LVEF was significantly higher than before treatment（P < 0.05）. After 6 months of treatment，compared with control group，the levels of NT ⁃ proBNP、LVEDV、LVESV 、ventricular remodeling and Incidence of heart failure were significantly lower（P < 0.05），and LVEF was evidently higher in the study group（P < 0.05）. However，There were no significant differences in the rates of readmission and adverse drug reactions between the two groups（P > 0.05）. Conclusions Early application of dapagliflozin can effectively reduce ventricular remodeling and improve cardiac function in patients with acute myocardial infarction after emergency PCI，with relatively good safety.